QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
作者信息
Monzani Alice, Genoni Giulia, Scopinaro Alice, Pistis Gianfranco, Kozel Daniela, Secco Gioel Gabrio
机构信息
Division of Pediatrics, Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Neonatal and Pediatric Intensive Care Unit, Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy.
出版信息
Eur J Clin Invest. 2020 Jun;50(6):e13258. doi: 10.1111/eci.13258. Epub 2020 May 18.
Abstract
摘要
相似文献
1
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.对接受氯喹/羟氯喹治疗的新冠病毒疾病患者进行QTc评估。
Eur J Clin Invest. 2020 Jun;50(6):e13258. doi: 10.1111/eci.13258. Epub 2020 May 18.
2
COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?2019冠状病毒病与羟氯喹-阿奇霉素联合用药：我们应该为患者冒这个险吗？
Br J Clin Pharmacol. 2020 Jun;86(6):1176-1177. doi: 10.1111/bcp.14335. Epub 2020 May 7.
3
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.接受羟氯喹和阿奇霉素治疗的新冠肺炎患者的QT间期。
Nat Med. 2020 Jun;26(6):808-809. doi: 10.1038/s41591-020-0888-2.
4
QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.在接受羟氯喹、氯喹或阿奇霉素治疗的不同城市新冠患者群体中QT间期延长。
J Interv Card Electrophysiol. 2020 Nov;59(2):337-345. doi: 10.1007/s10840-020-00822-x. Epub 2020 Jul 11.
5
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.新冠病毒感染患者使用氯喹/羟氯喹治疗时的QTc评估：致编辑的一封信
Eur J Clin Invest. 2020 Nov;50(11):e13407. doi: 10.1111/eci.13407. Epub 2020 Sep 25.
6
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.氯喹、羟氯喹和阿奇霉素用于治疗新型冠状病毒肺炎（SARS-CoV-2感染）时的安全性考量
CMAJ. 2020 Apr 27;192(17):E450-E453. doi: 10.1503/cmaj.200528. Epub 2020 Apr 8.
7
Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.羟氯喹和阿奇霉素治疗的 COVID-19 患者的心律失常谱和 24 小时 QT 间期变异性。
Int J Cardiol. 2020 Oct 1;316:280-284. doi: 10.1016/j.ijcard.2020.05.036. Epub 2020 May 19.
8
Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.探索性 COVID-19 治疗中药物相互作用对 QTc 间期的影响因素。
Heart Rhythm. 2020 Jul;17(7):e231-e232. doi: 10.1016/j.hrthm.2020.04.016. Epub 2020 Apr 14.
9
Saudi Heart Rhythm Society Task Force on Management of Potential Arrhythmogenicity Associated with Pharmacotherapy for COVID-19.沙特心脏节律学会关于新冠病毒病药物治疗相关潜在致心律失常性管理的特别工作组
Ann Saudi Med. 2020 Sep-Oct;40(5):365-372. doi: 10.5144/0256-4947.2020.365. Epub 2020 Oct 1.
10
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.氯喹、羟氯喹和阿奇霉素对 SARS-CoV-2 感染患者校正 QT 间期的影响。
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29.
引用本文的文献
1
Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients.评估住院 COVID-19 患者的潜在药物-药物相互作用和多药治疗情况。
Afr Health Sci. 2022 Dec;22(4):597-606. doi: 10.4314/ahs.v22i4.65.
2
The potential role of SARS-CoV-2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread.严重急性呼吸综合征冠状病毒 2 感染在急性冠状动脉综合征和 2 型心肌梗死（T2MI）中的潜在作用：交织传播。
Immun Inflamm Dis. 2023 Mar;11(3):e798. doi: 10.1002/iid3.798.
3
Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns.新型冠状病毒肺炎的心血管影响：并发症管理及药物安全性问题
J Res Med Sci. 2022 Dec 23;27:92. doi: 10.4103/jrms.jrms_895_21. eCollection 2022.
4
Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.COVID-19 感染患者羟氯喹治疗后 QTc 间期的变化：一项大型、回顾性、多中心队列研究。
BMJ Open. 2022 Feb 9;12(2):e051579. doi: 10.1136/bmjopen-2021-051579.
5
How to manage the abundant COVID-19 submissions to a peer-reviewed Scientific Journal.如何处理大量提交给同行评审科学期刊的新冠病毒相关稿件。
Eur J Clin Invest. 2021 Jun;51(6):e13569. doi: 10.1111/eci.13569. Epub 2021 Apr 13.
6
Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions.关于 COVID-19 和相关潜在药物相互作用导致病情恶化的合并症的荟萃分析。
Pharmacol Res. 2020 Nov;161:105250. doi: 10.1016/j.phrs.2020.105250. Epub 2020 Oct 13.
7
The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up.马德里一家医院的首批100例新冠肺炎病例，随访2个月。
Rev Esp Quimioter. 2020 Oct;33(5):369-378. doi: 10.37201/req/072.2020. Epub 2020 Jul 30.
8
Concentration-dependent mortality of chloroquine in overdose.氯喹过量致浓度依赖性死亡率。
Elife. 2020 Jul 8;9:e58631. doi: 10.7554/eLife.58631.
本文引用的文献
1
Concerns related to COVID-19 pandemic among patients with inflammatory bowel disease and its influence on patient management.炎症性肠病患者对新型冠状病毒肺炎大流行的担忧及其对患者管理的影响。
Eur J Clin Invest. 2020 May;50(5):e13233. doi: 10.1111/eci.13233. Epub 2020 May 9.
2
Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19.联盟：倡导开展前瞻性临床试验，以测试羟氯喹对COVID-19的暴露后预防潜力。
One Health. 2020 Apr 4;9:100131. doi: 10.1016/j.onehlt.2020.100131. eCollection 2020 Jun.
3
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.羟氯喹和阿奇霉素联合治疗至少随访 6 天的 80 例 COVID-19 患者的临床和微生物学效果：一项前瞻性观察研究。
Travel Med Infect Dis. 2020 Mar-Apr;34:101663. doi: 10.1016/j.tmaid.2020.101663. Epub 2020 Apr 11.
4
Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.优化 COVID-19 患者的羟氯喹剂量：一种有效的药物再利用的综合建模方法。
Clin Pharmacol Ther. 2020 Aug;108(2):253-263. doi: 10.1002/cpt.1856. Epub 2020 May 12.
5
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
6
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
7
The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm.新型冠状病毒（2019 - nCoV）感染：抗击疫情面临的挑战
Eur J Clin Invest. 2020 Mar;50(3):e13209. doi: 10.1111/eci.13209. Epub 2020 Feb 5.
8
Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland.实验室确诊的呼吸道感染作为急性心肌梗死和中风的诱因：苏格兰国家关联数据集的自我对照病例系列分析。
Eur Respir J. 2018 Mar 29;51(3). doi: 10.1183/13993003.01794-2017. Print 2018 Mar.
9
Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis.中东呼吸综合征冠状病毒（MERS-CoV）合并症的患病率：一项系统评价和荟萃分析
Int J Infect Dis. 2016 Aug;49:129-33. doi: 10.1016/j.ijid.2016.06.015. Epub 2016 Jun 21.
10
Cardiotoxicity of antimalarial drugs.抗疟药物的心脏毒性。
Lancet Infect Dis. 2007 Aug;7(8):549-58. doi: 10.1016/S1473-3099(07)70187-1.
Zotero 插件